Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Gains from Investment Securities (2016 - 2026)

Cytosorbents filings provide 12 years of Gains from Investment Securities readings, the most recent being $812800.0 for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities fell 90.66% to $812800.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $812800.0, a 90.66% decrease, with the full-year FY2025 number at $812800.0, down 90.66% from a year prior.
  • Gains from Investment Securities hit $812800.0 in Q4 2025 for Cytosorbents, down from $12.8 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $12.8 million in Q3 2025 to a low of $42499.0 in Q2 2022.
  • Median Gains from Investment Securities over the past 5 years was $5.8 million (2022), compared with a mean of $5.5 million.
  • Biggest five-year swings in Gains from Investment Securities: soared 48298.03% in 2021 and later tumbled 99.38% in 2022.
  • Cytosorbents' Gains from Investment Securities stood at $138037.0 in 2021, then skyrocketed by 5822.97% to $8.2 million in 2022, then rose by 29.02% to $10.5 million in 2023, then decreased by 17.52% to $8.7 million in 2024, then plummeted by 90.66% to $812800.0 in 2025.
  • The last three reported values for Gains from Investment Securities were $812800.0 (Q4 2025), $12.8 million (Q3 2025), and $12.2 million (Q2 2025) per Business Quant data.